Brimonidine
As of the edition of 20 October 2026, Brimonidine is a small molecule: marketed, first approved in 1996 (US); acts on ADRA2A, ADRA2B and ADRA2C; no US protection of its own is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2014
- Kind
- Small molecule
- Brand name
- Alphagan
- First approved
- 6 September 1996 (US)
- Approvals on record
- 25 in 7 regions
- Holder of the most recent approval
- Visus Therapeutics; 11 holders in all
- Registered trials
- 119, 13 stopped early
- Disease areas
- Eye; Skin and connective tissue; Heart and blood vessels; Hormones; Immune system; Chemically induced
US protection
No US protection of its own is listed.
The FDA registers list no drug-substance patent or exclusivity of its own that counts for this drug.
Visus Therapeutics holds a later exclusivity on its own new formulation or combination product, ending 2029; it does not protect the original drug.
This is the US only.
Companies that need a new molecule because of this drug
9 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product9 company-target rows are on route B because of Brimonidine.
See the 9 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 14 | 9 | 0 | 2 |
| Phase 1 | 11 | 9 | 0 | 0 |
| Phase 2 | 24 | 17 | 3 | 2 |
| Phase 3 | 34 | 29 | 0 | 4 |
| Phase 4 | 36 | 24 | 5 | 5 |
| All trials | 119 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AbbVie | Applicant and Lead sponsor of trials | 1996 to now |
| Alcon | Later holder and Lead sponsor of trials | 2003 to now |
| Sandoz | Later holder | 2006 to now |
| Senju Pharmaceutical | Applicant | 2012 to now |
| Galderma | Later holder | 2013 to now |
| Bausch Health | Later holder and Lead sponsor of trials | 2013 to now |
| Galderma | Applicant | 2014 to now |
| Novartis | Later holder | 2014 to now |